ConductScience.org, home
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
API referenceFor AI assistants

Trial · NCT01381692

Participant flow18

How many started, completed or left each group, period by period.

1 to 18 of 18

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDArm A (Phase I: Temsirolimus Dose Level 1, Rituximab, Bortezomib, Dexamethasone)7
Overall StudySTARTEDArm B (Phase I: Temsirolimus Dose Level 2, Rituximab, Bortezomib, Dexamethasone)2
Overall StudySTARTEDArm C (Phase I: Temsirolimus Dose Level 3, Rituximab, Bortezomib, Dexamethasone)0
Overall StudySTARTEDArm D (Phase I: Temsirolimus Dose Level 4, Rituximab, Bortezomib, Dexamethasone)0
Overall StudySTARTEDArm E (Phase II: Rituximab, Bortezomib, Dexamethasone)0
Overall StudySTARTEDArm F (Phase II: Temsirolimus, Rituximab, Bortezomib, Dexamethasone)0
Overall StudyCOMPLETEDArm A (Phase I: Temsirolimus Dose Level 1, Rituximab, Bortezomib, Dexamethasone)6
Overall StudyCOMPLETEDArm B (Phase I: Temsirolimus Dose Level 2, Rituximab, Bortezomib, Dexamethasone)2
Overall StudyCOMPLETEDArm C (Phase I: Temsirolimus Dose Level 3, Rituximab, Bortezomib, Dexamethasone)0
Overall StudyCOMPLETEDArm D (Phase I: Temsirolimus Dose Level 4, Rituximab, Bortezomib, Dexamethasone)0
Overall StudyCOMPLETEDArm E (Phase II: Rituximab, Bortezomib, Dexamethasone)0
Overall StudyCOMPLETEDArm F (Phase II: Temsirolimus, Rituximab, Bortezomib, Dexamethasone)0
Overall StudyNOT COMPLETEDArm A (Phase I: Temsirolimus Dose Level 1, Rituximab, Bortezomib, Dexamethasone)1
Overall StudyNOT COMPLETEDArm B (Phase I: Temsirolimus Dose Level 2, Rituximab, Bortezomib, Dexamethasone)0
Overall StudyNOT COMPLETEDArm C (Phase I: Temsirolimus Dose Level 3, Rituximab, Bortezomib, Dexamethasone)0
Overall StudyNOT COMPLETEDArm D (Phase I: Temsirolimus Dose Level 4, Rituximab, Bortezomib, Dexamethasone)0
Overall StudyNOT COMPLETEDArm E (Phase II: Rituximab, Bortezomib, Dexamethasone)0
Overall StudyNOT COMPLETEDArm F (Phase II: Temsirolimus, Rituximab, Bortezomib, Dexamethasone)0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01381692/flow

API referenceFor AI assistants